Each vial contains 5 mg of semaglutide, in lyophilized form.
Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1). An amino acid substitution at position 8 confers resistance to DPP-4 degradation, and an attached C18 fatty diacid chain promotes albumin binding, together extending its half-life substantially relative to native GLP-1.
Semaglutide is widely used as a reference GLP-1 receptor agonist in published research into incretin signalling. Reported study endpoints include receptor binding kinetics, cyclic AMP response, insulin secretion in isolated islet preparations, and gastric motility and energy balance measures in animal models.
Areas of published research
- Insulin secretion in isolated pancreatic islet preparations
- Food intake, body weight and gastric emptying rate in rodent models
- Glycaemic endpoints including HbA1c and fasting glucose in preclinical and clinical literature
- Receptor binding kinetics and cyclic AMP response, widely used as the reference GLP-1 comparator
For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.


Reviews
There are no reviews yet.